STING1 and neoplasm: Activation of STING signaling in human melanoma cell lines enhances their immunogenicity and susceptibility to lysis by tumor-infiltrating lymphocytes; conversely, defects in the STING signaling pathway protect melanoma cells from immune recognition by TILs and promote resistance to T cell–based immunotherapies (122, 123).